Albertina N.
- Country
- Portugal
- Department
- Serviço Hematologia e Oncologia Médica
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Blinatumomab and Combination Therapy Versus Standard of Care in Older Adults With Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Efficacy and Safety Evaluation of Crovalimab Versus Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
Data & Insights
Has run more than one trial at 65 of 192 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on cases involving IDH1 mutations. Their research encompasses innovative therapeutic approaches for patients who cannot receive intensive chemotherapy treatments.
- IDH1-mutated AML management
- Treatment strategies for chemotherapy-ineligible patients
- Combination therapy approaches
Rare Blood Disorders
The investigator focuses on treating Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare acquired blood disorder. Their work involves evaluating novel therapeutic options for patients who have not previously received complement inhibitor treatments.
- PNH treatment optimization
- Complement inhibition therapies
- Management of rare hematologic conditions
Therapeutic Innovation
The investigator's work centers on developing and evaluating new treatment approaches for hematologic conditions. Their expertise includes assessing novel therapeutic agents and their comparative effectiveness in treating blood disorders.
- Comparative treatment efficacy
- Novel therapeutic development
- Patient-specific treatment approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.